natgillin/translations-raw huggingface dataset:
ZALTRAP е хиперосмотичен разтвор, който не е разработен за съвместимост с вътреочната среда.
ZALTRAP is a hyperosmotic solution, which is not formulated for compatibility with the intraocular environment.
Zaltrap не трябва да се прилага при хора, които са свръхчувствителни (алергични) към афлиберсепт или към някоя от останалите съставки.
Zaltrap must not be used in people who are hypersensitive (allergic) to aflibercept or any of the other ingredients.
Zaltrap се използва за лечение на възрастни пациенти с метастатичен колоректален карцином (рак на дебелото черво, който се е разпространил в други части на тялото), за които лечението на базата на друго лекарство, оксалиплатин, не е било ефективно или ракът се е влошил.
Zaltrap is used to treat adults with metastatic colorectal cancer (cancer of the large bowel that has spread to other parts of the body) for whom treatment based on another medicine, oxaliplatin, has not worked or the cancer got worse.
Zaltrap се използва с FOLFIRI, лечение, комбиниращо лекарствата иринотекан, 5-флуороурацил и фолинова киселина.
Zaltrap is used with FOLFIRI, which is a treatment combining the medicines irinotecan, 5-fluorouracil, and folinic acid.
Zaltrap се прилага под формата на интравенозна инфузия с продължителност един час, в доза от 4 mg на килограм телесно тегло.
Zaltrap is given as an infusion into the vein over one hour, at a dose of 4 mg per kilogram body weight.
ZALTRAP се прилага чрез вливане (инфузия) в една от вените („интравенозно”) за лечение на напреднал рак на дебелото черво или ректума.
ZALTRAP is given by a drip (infusion) into one of your veins (‘intra-venous’) to treat advanced cancers of the colon or rectum.
ZALTRAP се прилага чрез вливане (инфузия) в една от вените („интравенозно”).
It is given by a drip (infusion) into one of your veins (‘intra-venous’).
ZALTRAP/FOLFIRI Отлагане на лечението или промяна на дозата
ZALTRAP/FOLFIRI Treatment delay or dose modification
Zalviso 15 микрограма сублингвални таблетки Суфентанил
Zalviso 15 micrograms sublingual tablets Sufentanil
Zalviso да се използва съгласно указанията в КХП, за да се гарантира правилна употреба и свеждане на риска до минимум.
Use Zalviso according to the guidance in the SmPC to ensure appropriate use and minimize risks.
Zalviso е „хибридно лекарство“.
Zalviso is a ‘hybrid medicine’.
Zalviso не трябва да се използва при деца и юноши под 18 години.
Zalviso should not be used in children and adolescents below 18 years.
Zalviso се предлага в опаковки по 1, 10 и 20 патрона, и групови опаковки, съдържащи 40 (2 опаковки по 20), 60 (3 опаковки по 20) и 100 (5 опаковки по 20) патрона, еквивалентни съответно на 40, 400, 800, 1 600, 2 400 и 4 000 сублингвални таблетки.
Zalviso is available in pack sizes of 1 and 10, 20 cartridges and multipacks containing 40 (2 packs of 20), 60 (3 packs of 20) and 100 (5 packs of 20) cartridges, equivalent to 40, 400, 800, 1,600, 2,400 and 4,000 sublingual tablets, respectively.
Zalviso съдържа оцветителя сънсет жълто FCF алуминиев лак (E110), който може да причини алергични реакции.
Zalviso contains the colouring agent sunset yellow FCF Aluminium Lake (E110), which may cause allergic reactions.
Zalviso съдържа сънсет жълто FCF алуминиев лак (E110)
Zalviso contains sunset yellow FCF Aluminium Lake (E110)
zamašen nos
Feeling weak
Zamaška ne odstranite.
Do not remove the stopper
Zamegljen vid, skleritis in vnetje očnice
Blurred vision, scleritis and orbital inflammation
Zamegljen vid, solzenje, občutljivost oči za svetlobo.
Blurred vision, tearing of the eye, eye sensitivity to light.
ZAP-70 отрицателен (n = 100)
ZAP-70 negative (n=100)
ZAP-70 положителен (n = 161)
ZAP-70 positive (n=161)
ZAP-70 среден (n = 160)
ZAP-70 intermediate (n=160)
Zapakirane so v pretisnih omotih po 14 kapsul.
They are provided in blisters containing 14 capsules each.
Zapisujte si vše, co jíte do stravovacího deníku včetně obsahu kalorií a tuků.
Write down what you eat in a food diary, including the calorie and fat content.
Zapisujte si vše, co jíte do stravovacího deníku, včetně obsahu kalorií a tuků.
Write down what you eat in a food diary, including the calorie and fat content.
Zaprtje
Constipation
zaprtje driska
Constipation Diarrhoea
zaprtje driska.
constipation diarrhoea
zaprtje,
Constipation
zaprtje,
Visual impairment
zaprtje, bruhanje
constipation, vomiting
zaprtje, bruhanje
Uncommon
Zaradi bolnikove varnosti poskrbite za ustrezne alarme za zdravilo INOmax ( 2 ppm predpisanega odmerka), NO2 (1 ppm) in FiO2 ( 0,05).
For patient safety, appropriate alarms must be set for INOmax ( 2 ppm of the prescribed dose), NO2 (1 ppm), and FiO2 ( 0.05).
Zaradi izbire živalskih vrst in omejenih raziskovanih parametrov neželeni učinki pramipeksola na nosečnost in fertilnost samcev niso bili v celoti pojasnjeni.
Due to the selection of animal species and the limited parameters investigated, the adverse effects of pramipexole on pregnancy and male fertility have not been fully elucidated.
Zaradi morebitne okvare sistema ali prekinitve električnega toka morate imeti na voljo nadomestno napajanje z baterijo in nadomestni sistem za dovajanje dušikovega oksida.
In the event of a system failure or a wall-outlet power failure, a backup battery power supply and reserve nitric oxide delivery system should be available.
Zaradi morebitnih aditivnih farmakodinamskih učinkov (mielotoksičnost) se priporoča previdnost, saj se zaradi sočasne uporabe lahko povečata nevarnost in stopnja resnosti hematološke toksičnosti zdravila Teysuno.
However, due to possible additive pharmacodynamic effects (myelotoxicity), caution is advised as co- administration may increase the risk and severity of haematologic toxicity of Teysuno.
Zaradi morebitnih neželenih učinkov ustekinumaba pri dojenčkih se je treba odločiti, ali naj mati med zdravljenjem in do 15 tednov po njem preneha dojiti ali naj se raje preneha zdraviti z zdravilom STELARA, ob upoštevanju koristi dojenja za otroka in koristi zdravljenja z zdravilom STELARA za mater.
Because of the potential for adverse reactions in nursing infants from ustekinumab, a decision on whether to discontinue breast-feeding during treatment and up to 15 weeks after treatment or to discontinue therapy with STELARA must be made taking into account the benefit of breast-feeding to the child and the benefit of STELARA therapy to the woman.
Zaradi možnih aditivnih učinkov je treba bolnikom svetovati, naj bodo previdni, če jemljejo hkrati s pramipeksolom še druga zdravila s sedativnim učinkom ali uživajo alkohol (glejte poglavja 4.5, 4.7 in 4.8).
Because of possible additive effects, caution should be advised when patients are taking other sedating medicinal products or alcohol in combination with pramipexole (see sections 4.5, 4.7 and section 4.8).
Zaradi možnih aditivnih učinkov svetujemo bolnikom previdnost pri jemanju drugih sedativnih zdravil ali alkohola v kombinaciji s pramipeksolom (glejte poglavja 4.4, 4.7 in 4.8).
Because of possible additive effects, caution should be advised when patients are taking other sedating medicinal products or alcohol in combination with pramipexole (see section 4.4, 4.7 and 4.8).
Zaradi možnosti, da zdravljenje s pemetreksedom povzroči trajno neplodnost, naj se moški pred začetkom zdravljenja posvetujejo o shranjevanju semena.
Owing to the possibility of pemetrexed treatment causing irreversible infertility, men are advised to seek counselling on sperm storage before starting treatment.
Zaradi možnosti, da zdravljenje s pemetreksedom povzroči trajno neplodnost, naj se moški pred začetkom zdravljenja posvetujejo o shranjevanju sperme.
Owing to the possibility of pemetrexed treatment causing irreversible infertility, men are advised to seek counselling on sperm storage before starting treatment.
Zaradi nizke vrednosti kalcija: motnje srčnega ritma (aritmija, razvije se zaradi hipokalciemije).
As a consequence of low calcium values: irregular heart beat (cardiac arrhythmia; secondary to hypocalcaemia).
Zaradi nizke vrednosti kalcija: napadi krčev, otrplost in tetanija (zaradi hipokalciemije).
As a consequence of low calcium values: seizures, numbness and tetany (secondary to hypocalcaemia).
Zaradi pomanjkanja študij kompatibilnosti tega zdravila ne smemo mešati z drugimi zdravili.
In the absence of other compatibility studies this medicinal product must not be mixed with other medicinal products.
Zaradi tega je potrebno nesteroidna protivnetna zdravila, vključno s COX-2 inhibitorji, in klopidogrel sočasno uporabljati previdno (glejte poglavje 4.4).
Consequently, NSAIDs including Cox-2 inhibitors and clopidogrel should be co-administered with caution (see section 4.4).
Zaradi tveganja za pojav krvavitev in hematoloških neželenih učinkov je potrebno takoj preučiti potrebo po določanju števila krvnih celic in/ali drugih ustreznih preiskav, kadar se v obdobju zdravljenja pojavijo klinični simptomi, ki nakazujejo krvavitev (glejte poglavje 4.8).
Due to the risk of bleeding and haematological adverse reactions, blood cell count determination and/or other appropriate testing should be promptly considered whenever clinical symptoms suggestive of bleeding arise during the course of treatment (see section 4.8).
Zaradi vaše varnosti in zdravja in varnosti drugih, uporabljene brizge ne smete ponovno uporabiti.
Never re-use a syringe, for your safety and health and for the safety of others.
Zaradi zgodnjega zaznavanja sprememb v ledvični funkciji med zdravljenjem je treba pozorno spremljati ledvične parametre (npr. kreatinin v serumu, CrCl).
To detect early changes in renal function during treatment, renal parameters should be closely monitored (e.g., serum creatinine, CrCl).
Zaragoza Испания
Zaragoza
Zaragoza Испания
Zaragoza Spain
Zaragoza, Испания
50.016 Zaragoza, Spain
Zarzio
Package size
Zarzio 30 MU/0,5 ml
Zarzio 30 MU/0.5 ml
Zarzio 30 MU/0,5 ml инжекционен или инфузионен разтвор в предварително напълнена спринцовка
Zarzio 30 MU/0.5 ml solution for injection or infusion in pre-filled syringe
Zarzio 30 MU/0,5 ml инжекционен или инфузионен разтвор в предварително напълнена спринцовка
Zarzio 30 MU/0.5 ml solution for injection or infusion in pre-filled syringe EU/1/08/495/001
Zarzio 30 MU/0,5 ml инжекционен или инфузионен разтвор в предварително напълнена спринцовка: Всяка предварително напълнена спринцовка съдържа 30 MU филграстим в 0,5 ml, съответстващо на 60 MU/ml.
Zarzio 30 MU/0.5 ml solution for injection or infusion in pre-filled syringe: Each pre-filled syringe contains 30 MU filgrastim in 0.5 ml, corresponding to 60 MU/ml.
Zarzio 30 MU/0,5 ml инжекция или инфузия
Zarzio 30 MU/0.5 ml injection or infusion
Zarzio 48 MU/0,5 ml
Zarzio 48 MU/0.5 ml
Zarzio 48 MU/0,5 ml инжекционен или инфузионен разтвор в предварително напълнена спринцовка
Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe
Zarzio 48 MU/0,5 ml инжекционен или инфузионен разтвор в предварително напълнена спринцовка
Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe EU/1/08/495/005
Zarzio 48 MU/0,5 ml инжекционен или инфузионен разтвор в предварително напълнена спринцовка: Всяка предварително напълнена спринцовка съдържа 48 MU филграстим в 0,5 ml, съответстващо на 96 MU/ml.
Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe: Each pre-filled syringe contains 48 MU filgrastim in 0.5 ml, corresponding to 96 MU/ml
Zarzio 48 MU/0,5 ml инжекция или инфузия
Zarzio 48 MU/0.5 ml injection or infusion
Zarzio e „биоподобно“ лекарство.
Zarzio is a ‘biosimilar’ medicine.
Zarzio да не се прилага при пациенти с анамнеза за свръхчувствителност към филграстим или пегфилграстим.
Do not administer Zarzio to patients with a history of hypersensitivity to filgrastim or pegfilgrastim.
Zarzio действа като стимулира костния мозък да произвежда повече бели кръвни клетки.
Zarzio works by encouraging the bone marrow to produce more white blood cells.
Zarzio не би трябвало да повлияе способността за шофиране и работа с машини.
Zarzio should not affect your ability to drive and use machines.
Zarzio не съдържа консерванти: Поради потенциалната опасност от микробна контаминация спринцовките Zarzio са предназначени за еднократна употреба.
Zarzio contains no preservative: In view of the possible risk of microbial contamination, Zarzio syringes are for single use only.
Zarzio не трябва да се разрежда с разтвор на натриев хлорид.
Zarzio must not be diluted with sodium chloride solutions.
Zarzio, съдържащ r-metHuG-CSF (филграстим), предизвиква значително повишаване на броя на неутрофилите в периферната кръв в рамките на 24 часа, при незначително увеличаване на моноцитите.
Zarzio containing r-metHuG-CSF (filgrastim) causes marked increases in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes.
Zaspanost
Somnolence
zaspanost ali nespečnost
leepiness or trouble sleeping
zaspanost,
Dizziness
Zaspanost.
Sleepiness.
Zato bo pri vas ali vašem otroku odvajanje od zdravljenja z zdravilom INOmax morda trajalo dan ali dva.
Thus it may take a day or two before you or your child is off INOmax therapy.
Zato fiksna kombinacija odmerkov (zdravilo Pravafenix) ne more veljati za medsebojno zamenljivo s sočasno uporabo enokomponentnih zdravil s fenofibratom in pravastatinom brez omejitev.
Therefore the fixed dose combination (Pravafenix) could not be considered interchangeable with the free co-administration of fenofibrate and pravastatin mono-component drug products.
Zato ibafloksacina ne smemo dajati mačkam, mlajšim od 8 mesecev.
Therefore, ibafloxacin should not be used in cats aged less than 8 months.
Zato je pred uporabo dušikovega oksida priporočljivo opraviti kateterizacijo pljučne arterije ali ehokardiografsko preiskavo osrednje hemodinamike.
It, therefore, is recommended that prior to the administration of nitric oxide, pulmonary artery catheterisation or echocardiographic examination of central haemodynamics be performed.
Zato je pri dajanju visokih odmerkov NSAID-ov ali acetilsalicilne kisline sočasno s pemetreksedom bolnikom z normalnim delovanjem ledvic (očistek kreatinina ≥ 80 ml/min) potrebna previdnost.
Therefore, caution should be made when administering higher doses of NSAIDs or aspirin, concurrently with pemetrexed to patients with normal function (creatinine clearance ≥ 80 ml/min).
Zato je treba bolnike opozoriti, da naj ne vozijo in upravljajo strojev, če se pojavi utrujenost.
Therefore, patients should be cautioned against driving or operating machines if this event occurs.
Zato je treba pri teh bolnikih skrbno spremljati ledvično funkcijo in pri veliki spremembi laboratorijskih parametrov zdravljenje s fenofibratom prekiniti.
The renal function of these patients must therefore be closely monitored and the treatment with fenofibrate stopped in the case of severe alteration of laboratory parameters.
Zato moramo vsem bolnikom, zdravljenim s pemetreksedom, naročiti, naj jemljejo folno kislino in vitamin B12 kot preprečevalni ukrep za zmanjšanje toksičnosti, povezane z zdravljenjem (glejte poglavje 4.2).
Therefore, all patients treated with pemetrexed must be instructed to take folic acid and vitamin B12 as a prophylactic measure to reduce treatment-related toxicity (see section 4.2).
Zato naj se palonosetron uporablja pri nosečih ženskah le, če zdravnik meni, da je to nujno potrebno.
Therefore, palonosetron should not be used in pregnant women unless it is considered essential by the physician.
Zato odsvetujemo uporabo živih oslabljenih cepiv (glejte poglavje 4.3 in 4.5).
As a result, concomitant use of live attenuated vaccines is not recommended (see section 4.3 and 4.5).
Zato se pričakuje, da bo izpostavljenost 5-FU v teh dveh skupinah primerljiva, saj dnevna izpostavljenost pri bolnikih s hudo ledvično okvaro temelji na odmerjanju zdravila Teysuno enkrat na dan, dnevna izpostavljenost 5-FU pri bolnikih z normalnim ledvičnim delovanjem pa na odmerjanju zdravila Teysuno dvakrat na dan.
Therefore, the daily exposure to 5-FU would be expected to be comparable in these groups, since the daily exposure in patients in the severe renal impairment group is based on the administration of Teysuno once a day, while the daily exposure to 5-FU in the patients with normal renal function is based on the administration of Teysuno twice daily.
Zato so interakcije z drugimi zdravili, ki bi vplivale na vezavo na plazemske proteine ali na izločanje z biotransformacijo, malo verjetne.
Therefore, interactions with other medicinal products affecting plasma protein binding or elimination by biotransformation are unlikely.
Zato so tu odmerki izraženi za obe obliki, za pramipeksol in pramipeksolijevo sol (v oklepaju).
Therefore, doses will be expressed in terms of both pramipexole base and pramipexole salt (in brackets).
Zato uporabe pemetrekseda pri bolnikih z očistkom kreatinina < 45 ml/min ne priporočamo (glejte poglavje 4.2).
Therefore, the use of pemetrexed in patients with creatinine clearance of <45 ml/min is not recommended (see section 4.2).
Zato zdravila Teysuno ni mogoče uporabiti kot nadomestka za druga peroralna zdravila 5-FU.
Therefore, Teysuno cannot be used as a substitute for other oral 5-FU products.
Zaventem Белгия
Zaventem Belgium
Zavesca 100 mg твърди капсули
Zavesca 100 mg hard capsules
Zavesca 100 mg твърди капсули Миглустат
Zavesca 100 mg hard capsules Miglustat
Zavesca действа като потиска ензима, наречен “глюкозилцерамид синтетаза” който е отговорен за първата стъпка в синтеза на повечето гликосфинголипиди.
Zavesca works by inhibiting the enzyme called ‘glucosylceramide synthase’ which is responsible for the first step in the synthesis of most glycosphingolipids.
Zavesca е прилаган в дози до 3 000 mg/ден в продължение до шест месеца при HIV позитивни пациенти по време на клинични изпитвания.
Zavesca has been administered at doses of up to 3000 mg/day for up to six months in HIV positive patients during clinical trials.
Zavesca може да се приема със или без храна.
Zavesca can be taken with or without food.
Zavesca се използва за лечение на лек до умерен тип 1 на болестта на Гоше при възрастни.
Zavesca is used to treat mild to moderate type 1 Gaucher disease in adults.
Zavesca се използва за лечение на следните групи пациенти: възрастни (18 и повече години) с болестта на Гоше тип 1 в лека до умерена форма.
Zavesca is used to treat the following patients: adults (aged 18 years and above) with mild to moderate type 1 Gaucher disease.
Zavesca се използва при пациенти, при които не е подходящо стандартното лечение с ензимозаместваща терапия (ЕЗТ); пациенти на всякаква възраст с болестта на Ниман-Пик тип С – потенциално фатално заболяване, при което гликосфинголипидите се натрупват в клетките на мозъка и в други части на тялото.
Zavesca is used in patients who cannot receive the standard treatment of enzyme replacement therapy (ERT); patients of all ages with Niemann-Pick type C disease, a potentially fatal disease in which glycosphingolipids build up within cells in the brain and elsewhere in the body.
Zavesca се използва също за лечение на прогресиращи неврологични симптоми при болестта на Niemann-Pick тип С при възрастни и деца.
Zavesca is also used to treat progressive neurological symptoms in Niemann-Pick type C disease in adults and in children.
Zavicefta 2 g/0,5 g pulver till koncentrat till infusionsvätska, lösning
Zavicefta 2 g/0.5 g powder for concentrate for solution for infusion
Zavicefta 2 g/0,5 g pulver till koncentrat till infusionsvätska, lösning ceftazidim/avibaktam
Zavicefta 2 g/0.5 g powder for concentrate for solution for infusion ceftazidime/avibactam
ZAVICEFTA 2 g/0,5 g pulver till koncentrat till infusionsvätska, lösning ceftazidim/avibaktam
ZAVICEFTA 2 g/0.5g powder for concentrate for solution for infusion ceftazidime/avibactam
Zavicefta administreras via intravenös infusion under 120 minuter med en infusionsvolym på 100 ml.
Zavicefta is administered by intravenous infusion over 120 minutes in an infusion volume of 100 mL.
Zavicefta används hos vuxna för att behandla:
Zavicefta is used in adults to treat:
Zavicefta fungerar genom att döda vissa typer av bakterier som kan orsaka allvarliga infektioner.
Zavicefta works by killing certain types of bacteria, which can cause serious infections.
Zavicefta innehåller natrium
Zavicefta contains sodium
Zavicefta kan orsaka yrsel.
Zavicefta may make you feel dizzy.
Zavicefta kan även påverka en del tester för socker i urinen.
Zavicefta can also affect the results of some urine tests for sugar.
Zavicefta ska inte användas på barn och ungdomar.
Zavicefta should not be used in children and adolescents.
Zavicefta ska inte blandas med eller fysiskt tillsättas till lösningar som innehåller andra läkemedelsprodukter.
Zavicefta should not be mixed with or physically added to solutions containing other medicinal products.
Zavicefta är avsett för behandling av följande infektioner hos vuxna (se avsnitt 4.4 och 5.1):
Zavicefta is indicated for the treatment of the following infections in adults (see sections 4.4 and 5.1):
Zavicefta är ett antibiotiskt läkemedel som innehåller de två aktiva substanserna ceftazidim och avibaktam.
Zavicefta is an antibiotic medicine that contains two active substances ceftazidime and avibactam.
Zavicefta är ett vitt till gult pulver till koncentrat till infusionsvätska, lösning, i en flaska.
Zavicefta is a white to yellow powder for concentrate for solution for infusion in a vial.
Zavicefta är även avsett för behandling av infektioner orsakade av gramnegativa aeroba organismer hos vuxna patienter med begränsade behandlingsalternativ (se avsnitt 4.2, 4.4 och 5.1).
Zavicefta is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adult patients with limited treatment options (see sections 4.2, 4.4 and 5.1).
Zavicefta самостоятелно (за инфекция на пикочните пътища) или в комбинация с метронидазол (за интраабдоминална инфекция) водят до сходен резултат спрямо известен брой алтернативни антибиотици при лечението на инфекцията: 91% от пациентите (140 от 154) са излекувани след лечение със Zavicefta в сравнение с 91% (135 от 148) след лечение с най-добрия алтернативен антибиотик.
Zavicefta alone (for urinary tract infection) or in combination with metronidazole (for intra-abdominal infection) provided similar results to a number of alternative antibiotics in curing the infection: 91% of patients (140 out of 154) were cured after treatment with Zavicefta compared with 91% (135 out of 148) after treatment with the best alternative antibiotic.
Zavicefta-infusionslösning är blekt gul och partikelfri.
The colour of Zavicefta infusion solution is pale yellow and free of particles.
Zaviralci/snovi, ki tekmujejo za aktivno pot izločanja skozi ledvice
Inhibitors/competitors of active renal elimination pathway
Zaviranje, ki so ga opazili po enkratnem odmerku oziroma po večkratnem odmerjanju, je bilo podobno.
Similar inhibition was seen following single and multiple dosing.
Zavrta je tudi agregacija trombocitov, ki jo izzovejo drugi agonisti kot ADP, ker pride do blokade ojačenja trombocitne aktivacije s sproščenim ADP.
Platelet aggregation induced by agonists other than ADP is also inhibited by blocking the amplification of platelet activation by released ADP.
Zaznamenávejte si, co jíte do stravovacího deníku.
Keep a record of what you are eating in a food diary.
Začetek zdravljenja:
Initial treatment
Začetni odmerek inhalacijskega dušikovega oksida je 10 ppm (delcev na milijon) vdihanega plina.
The starting dose of inhaled nitric oxide is 10 ppm(part per million) of inhaled gas.
Začetni odmerek inhalacijskega dušikovega oksida je 20 ppm (delcev na milijon) vdihanega plina.
The starting dose of inhaled nitric oxide is 20 ppm (part per million) of inhaled gas.
Začetni odmerek na prvi dan zdravljenja je 0,2 mg meloksikama na kilogram telesne mase.
Initial treatment is a single dose of 0.2 mg meloxicam/kg body weight on the first day.
Začnite takoj ko je mogoče, in v 4 do 24 urah zdravljenja omejite odmerek na 5 ppm, pod pogojem, da je arterijska oksigenacija pri tem najnižjem odmerku ustrezna.
Starting as soon as possible and within 4-24 hours of therapy, the dose should be weaned to 5 ppm provided that arterial oxygenation is adequate at this lower dose.